Pharmstandard International’s Protagonist Therapeutics PTGX Stock Holding History

Pharmstandard International’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$7.72M	Hold	750,632	–	–	26.59%	2
2018 Q2	$5.04M	Sell	750,632 -231,638	-24%	-$1.78M	20.23%	2
2018 Q1	$8.44M	Hold	982,270	–	–	21.2%	3
2017 Q4	$20.4K	Hold	982,270	–	–	21.01%	2
2017 Q3	$17.4M	Hold	982,270	–	–	50.6%	1
2017 Q2	$11.1M	Hold	982,270	–	–	38.52%	1
2017 Q1	$12.6M	Sell	982,270 -1,300	-0.1%	-$20.9K	33.57%	2
2016 Q4	$21.6M	Buy	+983,570	New	+$21.9M	18.63%	3

Other funds holding PTGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Pharmstandard International's PTGX Position: Q3 2018 in Review

Pharmstandard International held its Protagonist Therapeutics (PTGX) position steady in Q3 2018 at 750,632 shares worth $7.72M. The position accounts for 26.59% of the portfolio, ranked #2.

Pharmstandard International first reported a position in PTGX in Q4 2016 and has held it in 8 quarters since. The position peaked at $21.6M in Q4 2016. 61 funds tracked by Wall St. Rank hold PTGX as of Q3 2018.

Pharmstandard International held 750,632 shares of Protagonist Therapeutics worth $7.72M as of Q3 2018.
Pharmstandard International left its Protagonist Therapeutics share count unchanged in Q3 2018.
Protagonist Therapeutics made up 26.59% of Pharmstandard International's portfolio in Q3 2018, its #2 holding.
Pharmstandard International first reported a position in Protagonist Therapeutics in Q4 2016 and has held it in 8 quarters since.
Pharmstandard International's Protagonist Therapeutics position peaked at $21.6M in Q4 2016.
61 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2018.

Based on Pharmstandard International's 13F filing for Q3 2018, filed 15 Nov 2018.